Biotechnology company Biogen Idec Inc. < ... Biogen signs deal to develop electrolyte drug. By Reuters. August 9, 2007 9:10 PM UTC Updated July 2, 2007 BOSTON, July 2 ...

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets ...

When you think about biotech leaders, the name Biogen (BIIB-0.83%) may come to mind. Over the years, this biotechnology giant built a powerful multiple sclerosis (MS) treatment platform that has ...

As Biogen’s new CEO Chris Viehbacher pores over Biogen’s books and scouts out M&A deals, he may have one advantage his predecessor didn’t: a good relationship with his board of directors.

Biogen’s significant internal cost-cutting efforts have not deterred an aggressive hunt for deals, but CEO Chris Viehbacher doesn’t want infatuation to cloud necessary judgment. On a second ...